Can platinum compounds impair mitochondrial function and increase oxidative stress?

Platinum-based chemotherapeutic agents, such as cisplatin, are highly effective clinical tools whose systemic toxicities are closely linked to cellular energy depletion. Research shows these compounds impose a significant metabolic burden by directly targeting mitochondrial integrity and oxidative pathways.

Mechanisms of mitochondrial impairment and oxidative stress

• Mitochondrial DNA damage: Platinum compounds accumulate in the mitochondria and form covalent adducts with mitochondrial DNA (mtDNA), blocking replication and the transcription of essential electron transport chain (ETC) subunits.
• ETC inhibition and ROS generation: These agents directly inhibit mitochondrial respiratory complexes I–IV, causing mitochondrial membrane potential depolarization and massive reactive oxygen species (ROS) accumulation.
• Antioxidant depletion: Platinum exposure depletes vital mitochondrial glutathione (GSH) reserves, accelerating lipid peroxidation of mitochondrial membranes (including cardiolipin) and rendering cells highly vulnerable to oxidative damage.

Bioenergetic consequences and cellular impact

• ATP depletion: The combination of ETC disruption, diminished respiratory control ratios, and increased proton leaks severely restricts oxidative phosphorylation, leading to a rapid decline in ATP production.
• Cell death pathways: This systemic bioenergetic failure deprives highly metabolic tissues, such as renal and neuronal cells, of necessary energy, ultimately driving cell death via apoptotic or necrotic pathways.

Bottom line

• Platinum compounds systematically undermine cellular energy production by damaging mtDNA, directly inhibiting respiratory complexes I–IV, and depleting glutathione. The resulting oxidative stress and ATP depletion serve as primary drivers of chemotherapy-induced tissue toxicities.